4G·

The "mastermind" behind medical technology

Hey there, community ✌️

Today I’d like to introduce you to another candidate from my watchlist. Yesterday, $LGND (+2,41%) it was the royalty sector’s turn; today we’re focusing on medical technology! 🩺

For that, we’re turning our attention to Japan 🇯🇵 today, and I’ll be introducing you to the “mastermind” behind the medtech sector.

At the request of @PikaPika0105 , I put this presentation together on the fly and will try to sell this stock to him—and maybe one or two of you—today. 😏😂

Let’s go! 🚀

🧬 Asahi Intecc $7747 (+1,42%) : The invisible mastermind behind global surgery

Asahi Intecc $7747 (+1,42%) is not a conventional medical technology company that markets directly to patients. It is the global technological monopolist in the field of ultra-fine wire technology. While other companies sell catheters or stents under their own brand names, Asahi supplies the critical, irreplaceable “inner workings” for these products. Its proprietary manufacturing process allows it to bend wires as thin as a human hair while enabling absolute control (torque transmission)—this is the “high-fidelity connection” between the surgeon and the surgical site.

1. The Business Model: The Triad of Wire Dominance 🔬⚙️📈

Asahi controls the entire process of minimally invasive surgery through three pillars:

Core Technology (Only-One Manufacturing): Asahi masters the integration of metal and polymer technologies at the microscopic level. They don’t just produce wire; they engineer precision of movement. In cardiology, their guidewires are the global gold standard—when a surgeon clears a complicated blockage, they reach for Asahi almost without hesitation.

The OEM software layer (partnerships): The largest medtech giants (Boston Scientific $BSX (+1,06%) , Medtronic $MDT (+0,43%) , Edwards Lifesciences $EW (-0,48%) are not competitors, but paying partners. They rely on Asahi’s precision components to make their own catheter systems marketable in the first place. Asahi $7747 (+1,42%) is thus “embedded” in every major medtech ecosystem.

Global Expansion & Vertical Integration: Asahi $7747 (+1,42%) is aggressively expanding into its own end products (complete catheter systems) to capture the margins previously held by intermediaries. By focusing on robotic surgery and neurovascular procedures, the company is securing access to the fastest-growing fields in medicine.

2. Key Figures (Q3 2026 / FY2026) 📊

Market Capitalization: approx. 890–900 billion JPY (listed on the TSE Prime Market).

Revenue growth: Structural organic growth of 11–14% p.a. (in local currency), driven by demographic changes and the global shift from open surgery to minimally invasive procedures.

Gross margin:
Strong at ~67–70%. A phenomenal figure for a hardware manufacturer, underscoring its extreme pricing power due to its “only-one” technology.

Operating profitability: The operating margin remains consistently in the range of 22–25%. Asahi continues to consistently reinvest significant funds in R&D and capacity expansion (e.g., plants in Thailand and Vietnam) to keep imitators at bay.

Balance Sheet Strength: A flawless net-cash company (net debt/EBITDA ~ -0.4x). No significant debt risks, massive liquidity buffers. Growth is financed organically from operating cash flow.

3. Why is the stock exciting?

🚀1. Its “hidden champion” status: The market often underestimates the fact that Asahi is not just a standard supplier, but a systemically critical partner to the entire global surgical industry. Every minimally invasive surgery is a potential source of revenue for Asahi.

🚀2. Scaling & Capacity Expansion: The new production facilities in Thailand and Vietnam are increasingly coming online. Economies of scale are supporting the gross margin despite global cost pressures.

🚀3. Robotics as a Future Technology: Asahi is gearing up for robot-assisted surgery. As robots replace the surgeon’s hand, the demand for even more precise, sensor-equipped wire technology will rise—precisely Asahi’s area of expertise.

🚀4. Demographics as an Irrefutable Tailwind: The world’s aging population requires more cardiological, vascular, and neurovascular procedures. This is secular growth that remains virtually unaffected by recessions.

4. Risks ⚠️

❗️Currency risks (JPY): As a Japanese exporter (>70% of revenue generated abroad), currency fluctuations (particularly EUR/JPY and USD/JPY) cause apparent fluctuations in the figures upon conversion.

❗️Valuation at current levels: At exchange rates around ~3,689 JPY (P/E ratio ~32x), short-term growth is already largely priced in. The margin of safety relative to the base-case fair value (~2,850 JPY) has narrowed.

❗️Regulation: Delays in approval processes for new medical devices worldwide (FDA/MDR) can occasionally extend the time-to-market for new innovations.

🎯 EARNINGS PREP: ASAHI INTECC $7747 (+1,42%)

Date: Thursday, August 13 / Friday, August 14, 2026 (Official IR slot: 3:30 p.m. Tokyo local time)

Reporting Period: Q4 & Full Year FY2026 (Fiscal year-end: June 30, 2026)

since the stock price is at ~3,689 JPY is trading near its all-time high and the bar is set high.

1. 📊 EXPECTATIONS

Since these are the full-year results (FY2026) including the new guidance for FY2027, the market is scrutinizing them extremely closely:

Consensus revenue (Q4): ~34.7 billion JPY

Consensus EPS (Q4): ~17.3 JPY

Full-Year Revenue FY2026: Target is ~136–138 billion JPY (~14–15% YoY growth)

FY2027 Guidance: Crucial for the stock’s performance. The market expects further double-digit earnings growth (>12%) for FY2027.

My personal conclusion & Reaper Bonus 🧐

Asahi Intecc $7747 (+1,42%) is, in my view, one of the most exciting examples of how a company can build a real moat in a small niche often overlooked by the general public. Not a speculative tech stock, but a highly profitable medtech powerhouse with tremendous technological expertise.

Earnings are due next week, and I’m firmly convinced that $7747 (+1,42%) it will once again deliver strong results and blow expectations out of the water. 🔥

💀Jack’s Verdict:

“Forget short-term hype. Asahi Intecc is the kind of stock you hold in your portfolio and watch mature over the years. They provide the tools without which modern cardiology would simply grind to a halt—regardless of whether Medtronic, Boston Scientific, or Edwards ultimately comes out on top. The balance sheet is rock-solid. The only downside right now: The market has rediscovered the stock’s quality and driven the price up to nearly ¥3,700. No reason for panic for existing investors, but anyone looking to buy now should wait patiently for market noise toward the ¥2,850 to ¥3,000range.”

Reaper Rating: 🟡 HOLD / ACCUMULATE ON DIPs

DIP-BUYING RANGE: ¥2,800–¥3,000

Reaper Score:
7.5 / 10
(Quality remains at 9/10; the score is temporarily capped at ~3,689 JPY due to the valuation).

@Get_Rich_or_Die_Tryin
@Tenbagger2024
@PikaPika0105
@Multibagger
@Raketentoni And of course, everyone else ✌️

Have a great weekend, everyone 🫶

15 Commenti

Raketentoni@Raketentoni

Hey Brian (@Aktienhauptmeister)! 🚀

With **Asahi Intecc (TYO: 7747)**, you’ve picked out a true “hidden champion” of the Japanese medical technology sector. The story of the “invisible mastermind” makes for a great read, and the business model has a real moat.

But as always on our dissection table: the story is one thing, the bare facts are another. I’ve put your statements, “Jack’s Conclusion,” and the weekly charts through the wringer.

Here’s the detailed comparison: What in your analysis is **ABSOLUTELY CORRECT** and where you—or Jack—have **DISTORTED IMPORTANT FACTS**!

---

### 1. What in your analysis is SPOT ON ✅

* **Market dominance:**
Your description of the monopoly is spot on. Asahi Intecc holds an estimated **70% global market share in PTCA guidewires (coronary)**.

* **Growth & Margin:**
Your profitability figures are extremely accurate. The gross margin currently stands at an impressive **70.1%**. The operating margin is **24.5%**. Revenue growth in the past fiscal year was a strong **12%** (over 115 billion JPY).

* **Balance Sheet Strength:**
You praise the balance sheet, and rightly so. The company has a very low debt-to-equity ratio (**0.25**). Its cash and cash equivalents are offset by only **7.2 billion JPY** in debt. The company can finance itself.

* **Earnings Date:**
The date for the Q4/FY26 earnings report on **August 14, 2026** is absolutely correct.

---

### 2. Where You and Jack Are Distorting Reality (The Blind Spots) ❌

This is where it gets dangerous, because you’re ignoring fundamental risks and valuation metrics:

#### ❌ 1. Misreading Market Capitalization

* **Your statement:** approx. 890–900 billion JPY.
* **The fact:** The current market capitalization is significantly higher, at **978.8 billion JPY**.

#### ❌ 2. Concealing concentration risk

* **Your statement:** You’re hyping expansion into the future technologies of “robotics” and “neurovascular procedures.”
* **The fact:** That’s a long way off. In the harsh reality of the present, **72% of total revenue** comes solely from the cardiovascular segment (heart/blood vessels). The new areas you mentioned (neurovascular and gastrointestinal) currently account for **less than 15%** of the portfolio. This represents a massive concentration risk should treatment methods in cardiology change.

#### ❌ 3. The Valuation Trap (Forward P/E)

* **Your statement:** P/E ratio of ~32x at a share price of around 3,689 JPY.
* **The fact:** That’s just the backward-looking LTM P/E ratio (trailing). The much more important **forward P/E ratio (estimated) for FY26 stands at a hefty 52.5x**! That’s a massive premium compared to the Japanese industry average for medical technology, which is just **~15x**. The stock is currently extremely overvalued and already prices in all potential growth.

#### ❌ 4. Jack’s Fictitious “Fair Value”

* **Jack’s Statement:** Base-case fair value is ~2,850 JPY.
* **The Fact:** InvestingPro’s purely mathematical fair value model estimates the fair value at **3,716 JPY**. At a current price of **3,689 JPY**, the stock thus has a minimal upside of **0.75%**. Jack’s 2,850 JPY is far too low given the current metrics.

---

### 3. Chart Analysis & Technical Signals (Weekly Basis) 📉

* **Trend:**
The stock has staged a massive rally over the past 12 months and is up **+52.6%**.

* **Distance from Highs:**
At **3,689 JPY**, the stock is trading just barely below its 52-week high of **3,941 JPY** (currently at 93.7% of the high).

* **Indicators:**
On a weekly basis, both the moving averages and the oscillators signal a clear **"Strong Buy"**. Momentum remains fully intact.

* **Problem:**
As mentioned above, the price has reached almost exactly its fair value (+0.75% margin). Technically strong, but fundamentally stretched.

---

### 4. The Final Verdict 🎯

**Asahi Intecc** is a quality powerhouse with over 1,800 global patents and pricing power that others can only dream of. Its business model is unassailable.

**But:** With a forward P/E of 52.5x, the stock is currently in full “priced-for-perfection” mode. If the company stumbles even slightly with its FY27 guidance on August 14, 2026, the market will punish this valuation mercilessly.

Jack’s conclusion to wait for pullbacks is strategically the absolutely right decision—even if he should fine-tune his valuation and fair value figures a bit more!

Greetings from Denmark

Yours, Raketentoni

•

Helge@Schneider

Awesome company—it would also be a great fit for the " $LGGG." Thanks for the insight 👍🏼 It's going on my watchlist

•

Brian@Aktienhauptmeister

@Schneider It flies completely under the radar and, in my opinion, is underrated!

•

Invest2impress@Invest2impress

What kind of companies are you pulling out of thin air here? 🚀 Add me to your watchlist right away 👍 Thanks for the introduction

•

Tenbagger2024@Tenbagger2024

Hi there, once again, a great company. The Japanese really know their stuff. But I wonder how AI will change this industry, and whether microrobots could hurt the company? @PikaPika0105

•

Get_Rich_or_Die_Tryin@Get_Rich_or_Die_Tryin

Great company—you know what I think about it. But even here, I'd wait for a pullback.😘

•

Brian@Aktienhauptmeister

@Get_Rich_or_Die_Tryin For a lot of values, I have to wait for a reset 😭

•

PikaPika0105@PikaPika0105

Thanks, very interesting. A perfect example of a Japanese B2B interface. Virtually no debt and a good geographic distribution of revenue. Demand is also set to rise steadily. Economically speaking, the next decade will once again belong to the Japanese. Companies with these kinds of values will be among the leaders.

The funny thing is that this hasn’t been recognized at all in the West so far. I recently conducted a comparative analysis of the 100 largest Japanese and German companies. The results were astonishing. Japanese companies were active in future trends to a significantly greater extent, they were more diversified, and they generated significantly higher revenue and profits. The German top 100, on the other hand, were active in vulnerable or dying sectors by more than two-thirds, with high concentration risk; they were less profitable and involved in only a few future trends. Only a small, elite group within the top 100 stands out from the rest (e.g., Siemens, Zeiss, Merck, Siemens Energy, Infineon…), while the vast majority seems to be heading toward the cliff (traditional manufacturing, chemicals, automotive suppliers, internal combustion engines…). This result should give us pause for thought, especially when we keep hearing fairy tales about Japan’s decline. We can no longer afford this kind of arrogance.

I currently see very clear parallels to Japan in the 1990s. Back then, the Japanese faced major problems, such as the bursting of a real estate bubble, but they were also overtaken technologically in many areas. In addition, they failed to keep up with future trends (the Internet, software…). The consolidation that was set in motion afterward—strategically, economically, politically, and in terms of corporate management—took 25–30 (!) years. The 2020s mark a new beginning. Many corporate transformations are now gradually being completed (e.g., Sony, Fujifilm, Panasonic, Toshiba Memory/Kioxia, Hitachi, NEC…). Furthermore, the Japanese are now profiting from nearly every future trend through their specialized B2B companies (e.g., Murata, TDK, Kyocera, Shin-Etsu, Ibiden, Fujifilm, Ajinomoto, Disco, Furukawa, Osaka Titanium, Harmonic Drive, Nabtesco, Tokyo Electron…), without ever coming into contact with consumers. When these products gradually disappear from store shelves, consumers interpret this as economic decline, but the opposite is true. The products simply become invisible to consumers; however, they are still there, generate higher margins than before, and are significantly harder to replace.

I think that a period of consolidation like this is inevitably on the horizon for us as well. Perhaps it will only take 15 years here, but it will require a great deal of time. Politicians are unable to implement reforms, a challenge made even more difficult by increasing polarization. Companies will need a long time to realign themselves, but they currently lack direction and face glaring locational disadvantages. I’m really curious to see how we’ll all view Germany and Japan in 10 years. Of course, I’d like to see both countries succeed, but if I had to choose, I know which portfolio of companies I’d bet on right now.

•

Brian@Aktienhauptmeister

@PikaPika0105 Aside from the big medtech companies, I think Asahi Intecc is totally underrated! I opened a small position a few weeks ago and am continuing to build it up. It’s awesome that you’re familiar with Disco and Nabtesco, too—especially Disco, which I find to be the most interesting company in the semiconductor sector alongside Rorze, Lasertec, and Hoya. Nabtesco is a medtech supplier, and not many people know about it either. 🫶

•

PikaPika0105@PikaPika0105

@Aktienhauptmeister I recently bought Xvivo Perfusion from Medtech. They're revolutionizing organ transplantation.

•

Brian@Aktienhauptmeister

@PikaPika0105 I recently came across Edap Tms, a medtech company from France. At first glance, it looks really interesting. But I haven't had time to dig deeper yet. Its stock performance over the last few years has been impressive, too. I'd love to hear your thoughts on it 👀

••

PikaPika0105@PikaPika0105

@Aktienhauptmeister I think they just changed their name to Focal Therics. They aren't really well represented on Trade Republic. They aren't projected to turn a profit until fiscal year 2030. There will definitely be several more stock dilutions. I'd be more inclined to go with Xvivo and Asahi.

•

Johnny B.@JBatelli

Thanks, I hadn't heard of that before. Interesting. A "hidden champion" that challenges the system, with pricing power and huge margins.

•

Brian@Aktienhauptmeister

@JBatelli In my opinion, it's completely undervalued! I opened a small position a while back and will continue to increase it.

•

Herr J.@goldi1971

That's very interesting. I'm actually looking to expand my portfolio in the medical technology sector right now. So this presentation comes at just the right time. Thank you very much.

•